SCP Foundation Secure, Contain, Protect About About Us Site Rules FAQ Licensing Criticism Policy Article Deletions Community Site News IRC Chat Authors' Pages Artist Directory Contest Archive Staff List Resources Guides Essays & Resources Wiki Syntax Sandbox Usertools Sister Sites SCP International Wanderer's Library Contact Us ≡ About About Us Site Rules FAQ Licensing Criticism Policy Article Deletions Contact Staff Community Site News IRC Chat Authors' Pages Artist Directory Contest Archive Staff List Resources Guides Search this site Search • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ • ◦ ◦ • • ◦ ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ Essays & Resources Wiki Syntax Sandbox Usertools Sister Sites SCP International Wanderer's Library Create account or Sign in Getting Started Guide for Newcomers Join the Site Contribute | FAQ Universe Hub Main | Forum SCP by Series I | II | III | IV | V VI | VII | VIII | IX Other SCP Explained | Joke International Feed New Pages Shortest | Top Rated Recent Changes New Forum Posts Lowest Rated Pages Stories Tales Hub | Series Groups of Interest GoI Formats Canon Hub Discovery Artwork Hub Curated Lists Curated Tale Series Tag Search Random SCP | Tale | GOI | Art Random Page ◦ ◦ ◦ ◦ • ◦ ◦ SCP-7875 rating: +30+–x Item#: 7875 Level3 Containment Class: keter Secondary Class: none Disruption Class: keneq Risk Class: danger link to memo Special Containment Procedures: All in vitro samples of SCP-7875 are to be stored in a ULT Freezer1 in Site-92's Pathology Wing. Testing with SCP-7875 must be approved by Dir. McIntyre, with Level-3 personnel or higher supervising said testing has been suspended until further notice. In the event of a mechanical failure of said storage units, mobile Scranton Reality Anchors (SRAs) are to be deployed to ensure the containment of all in vitro samples.
Any personnel found to be infected2 with SCP-7875 are to be immediately quarantined within a modified Negative Pressure Isolation Unit (NPIU)3. Under no circumstances are healthy Foundation personnel permitted close contact with SCP-7875-a instances. Any physical interactions with infected instances must be conducted via Remote-Piloted Medical Drones (RPMDs).
Should an instance of SCP-7875-a expire, or otherwise attempt to breach containment, attending personnel are to immediately enact the following procedure.
Protocol Asclepius Phase Title Description I Thermal Treatment Upon immediate cessation of life-functions, SCP-7875-a, and its subsequent containment chamber, are to be incinerated by a team of modified RPMD units. The interior of the chamber must reach temperatures of at least 800°C to ensure the destruction of all organic materials. The cremated remains of SCP-7875-a are to be collected and disposed of in accordance with the Foundation Disposal Guidelines for Biohazardous Materials II Decontamination Following the removal of the prior instance, all surfaces of the chamber are to be thoroughly coated in DIA-1494. This solution is to remain for a minimum of 15 minutes before implementation of Phase III III UV-Hume Irradiation Until the admission of a new SCP-7875-a instance, the chamber is to remain constantly UV irradiated via mobile UVC lamps. In addition to this, the retrofitted SRAs are to implement widespread genomic annihilation of the Acinetobacter genus A space-filled 3D model of the proposed quaternary structure for SCP-7875-1 Description: SCP-7875 denotes a previously unidentified, extremophilic strain of Acinetobacter baumannii. Found exclusively in Site-92's Medical Wing, SCP-7875 shares many similarities to other members of its species, primarily in regards to their nosocomial nature5 and general cellular anatomy. Where SCP-7875 differs from other strains is its expression of SCP-7875-16.
A 0.97 MDa protein complex, expression of SCP-7875-1 results in the absorption of ambient Hume levels in its immediate environment. While this typically results in mild spatial distortions in non-organic environments like medical equipment, when present in living organisms, the reduction of Hume levels gradually dematerializes the host's affected tissue7.
In addition to this ontokinetic manipulation, SCP-7875 has also displayed an anomalously high level of genetic plasticity. While the exact mechanism behind such plasticity is under investigation, current hypotheses link this genetic reparability to the heightened expression of RecA proteins8. It is further believed that SCP-7875-1 contributes to this anomalously rapid activity, converting excess ontokinetic energy from the absorbed Hume Fields into mechanical energy for these RecA proteins.
Due to this rapid rate of genetic alteration, treatment of SCP-7875 infections have become increasingly difficult. While the onset of symptoms in those infected progresses at a rate comparable to other A. baumannii strains, SCP-7875's reparability has rendered all available anti-biotic treatments nigh-ineffective. Presently, Adaptive Phage Therapy (APT) has proven to be the only viable means of counteracting said infections.
Should an SCP-7875-a instance be left untreated, or otherwise succumbs to their infection, SCP-7875 will completely dematerialize the infected subject. Upon reaching this stage, the remaining SCP-7875 colonies will proceed to restructure themselves into a biofilm, effectively laying dormant until a new subject has been infected.
For details surrounding the discovery of SCP-7875, see Addenda 7875-1 through -5.
Addendum 7875-1: Excerpt from Project Panacea Proposal PROJECT PANACEA Dr. E. Aldrich, Dr. R. Carvalho, Dr. Y. Hasashi Introduction Since the emergence of streptomycin resistant M. tuberculosis in the 1940's, humanity has remained in a persistent struggle against anti-microbial resistant (AMR) bacteria.
Pathogens like S. aureus and the aforementioned M. tuberculosis, once thought to be treatable through the use of anti-biotics, re-emerged more potent than before. While the discoveries made during the so called "Golden Age of Anti-Biotics" kept many of these AMR bacteria at bay, human exploration and innovation could only stretch so far. This well-intentioned, but flawed effort resulted in many of the Multidrug-Resistant Pathogens (MDRPs) seen today, ravaging both public and Foundation-affiliated healthcare facilities alike.
Specifically in regards to the latter, Site-47's Logistics Division has reported a staggering ███ deaths across all Foundation Sites as a direct result of such infections in 2022 alone, up 175% from 2019's toll. While this value is ultimately a culmination of various AMR bacterial infections, one pathogen in particular that has resulted in upwards of 65% of such deaths is Acinetobacter baumannii.
An opportunistic, Gram-negative bacterium, A. baumannii has displayed an unnatural level of resistance to nearly all classes of available anti-biotics. While research has strongly affiliated this resistance to the expression of the RecA protein complex, efforts to effectively target this DNA repair complex have been futile. As a result, polymyxins are one of the few viable therapeutic avenues capable of halting the spread of A. baumannii infections. However, the limited supply of such anti-biotics can not nearly match the ever increasing demand, leaving many patients in dire need for new, innovative treatment options. This is in addition to the ever-increasing risk that A. baumannii will eventually develop resistance pathways to counteract polymyxin treatment.
While this would almost certainly spell doom for public healthcare facilities, pathological research conducted throughout Foundation facilities has already begun exploring promising alternatives to anti-biotic treatments. One of the most notable candidates, which this proposal will further explore, is an experimental therapy whose aim is to completely eradicate the presence of foreign pathogens in a host's body. Currently dubbed "Hume Therapy", this treatment utilizes an array of modified Scranton Reality Anchors to target the genetic sequence of a pathogen, in this case, A. baumannii, and counteract its Hume signature with an opposing field. This interaction between the two fields effectively results in the erasure of the targeted pathogen from baseline reality.
Materials & Methodology Genomic Hume Targeting Using early schematics of Dr. Scranton's eponymous Reality Anchors, Dr. Hasashi and her colleagues in the Department of Applied Ontokinetics were able to integrate a series of modifications into said SRA models. Such adjustments included the insertion of components like a MicroKant Scanner, and a Prokaryotic BLAST Database, amongst others which can be found in Figure 2c. By implementing these modifications, the newly dubbed Genomic Reality Anchors (GRAs) were able to effectively scan for and target genetic sequences inherently unique to the model organism in question.
Much like a matter-antimatter annihilation event, this targeting would induce a counter- field to negate the natural Hume signature of the genetic sequence in question, erasing it from baseline reality. By mapping out genomic regions vital to the pathogen's survival, the erasure of these sequences would induce a widespread apoptotic event throughout these foreign bodies, while leaving the host unharmed.
Model Organisms The model organisms that were used in this study were provided by Site-107's Department of Microbiology. These organisms included the following; Acinetobacter baylyi (Variants 87, 105, 149, 289, 302, and 375), Escherichia coli variant 401, and Enterococcus faecalis variant 269. All organisms were handled and grown in accordance to the Foundation Regulatory Guidelines for Microorganism Experimentation. Also provided by Site-107 were 5 Mus musculus subjects for in vivo testing. As with the previously mentioned bacteria, all Mus musculus organisms were handled and cared for in accordance to the Foundation Ethical and Regulatory Guidelines for In Vivo Experimentation.
Results Objective Test Subject Result Ensure the efficacy of Hume Therapy on single bacterium species A single Petri Dish of Acinetobacter Baylyi Complete ontokinetic annihilation of all present bacterial colonies Ensure the accuracy of Hume Therapy in the presence of numerous bacterial species A multi-streaked Petri Dish consisting of A. baylyi9, E.
coli, and E. faecalis Complete ontokinetic annihilation of A. baylyi. E. coli and E. faecalis colonies remained untouched.
Ensure the accuracy of Hume Therapy in the presence of related bacterial species A multi-streaked Petri Dish consisting of 6 variants of A. baylyi10 Complete ontokinetic annihilation of V149, with the other 5 variant colonies remaining unharmed Observe the effects of Hume Therapy in an in vivo model Mus musculus infected with attenuated, pathogenic variant of A.
baylyi Complete ontokinetic annihilation of A. baylyi. No detrimental effects observed in model organism The following figure is a summary of all pre-clinical testing done using Hume Therapy on a variety of model organisms. Testing was primarily conducted by Dr. Riccardo Carvalho, under the direct supervision of Dr. Aldrich and Dr. Hasashi Addendum 7875-2: Clinical Trial Proposal To: Aldrich, Ethan (gro.tenpics|e.hcirdla#gro.tenpics|e.hcirdla) From: McIntyre, Kieran (gro.tenpics|k.erytnicm#gro.tenpics|k.erytnicm) Date: 24/05/2022 Subject: Clinical Trial Proposal: PROJECT PANACEA Dr. Aldrich, I hope you've been adjusting well at Site-403. I just wanted to reach out and let you know that the Ethics Committee and I have officially reviewed your Clinical Trial Proposal, and are prepared to greenlight it. Before we do though, we have one minor concern we were hoping you could clear up first.
We noticed that, under the Personnel section that you listed Dr. Carvalho as the Lead Medical Researcher for this stage of the project. While I have no doubt that he is a talented researcher given their prior track record, the significance and inherent risk behind handling such trials is no small order. Are you sure he's ready to bear the responsibility of such testing?
-Dir. McIntyre To: McIntyre, Kieran (gro.tenpics|k.erytnicm#gro.tenpics|k.erytnicm) From: Aldrich, Ethan (gro.tenpics|e.hcirdla#gro.tenpics|e.hcirdla) Date: 26/05/2022 Subject: Re:Clinical Trial Proposal: PROJECT PANACEA Dir. McIntyre, Thank you so much for reaching out. Your concern over Dr. Carvalho is completely understandable, given his lack of prior exposure in such scenarios. However, I can assure you he is absolutely ready to take charge of these trials. Dr. Carvalho is as meticulous of a researcher as he is brilliant. His reliability and ingenuity in my lab is second to none, and leaves me completely comfortable putting him in charge during my absence.
Plus, he won't be conducting all of this on his own, either. Dr. Hasashi will be personally supervising all GRA operations, and I already plan to check-in with him frequently for status reports on each patient.
If you have any other questions, I'd be more than happy to answer them.
Best, Dr. Aldrich To: Aldrich, Ethan (gro.tenpics|e.hcirdla#gro.tenpics|e.hcirdla) From: McIntyre, Kieran (gro.tenpics|k.erytnicm#gro.tenpics|k.erytnicm) Date: 05/06/2022 Subject: Re:Clinical Trial Proposal: PROJECT PANACEA Dr. Aldrich, Given the rather urgent nature of this project, I'll trust your instinct on this. I don't believe I have any other questions though, so I'll go ahead and greenlight your project.
Best of luck!
Dir. McIntyre ‡ Licensing / Citation Cite this page as: "SCP-7875" by DrRevan, from the SCP Wiki. Source: https://scpwiki.com/ scp-7875. Licensed under CC-BY-SA.
For information on how to use this component, see the License Box component. To read about licensing policy, see the Licensing Guide.
Filename: [1q3s EBI.jpg|PDB_1q3s_EBI] Name: PDB 1q3s EBI Author: Jawahar Swaminathan License: Public Domain **Source Link:*https://www.ebi.ac.uk/pdbe/entry/pdb/1q3s Footnotes 1. A temperature-controlled storage unit used to keep samples at temperatures ranging from −40 to −80 °C 2. Henceforth designated SCP-7875-a 3. These units have been notably retrofitted with 2 SRA units to negate the effects of SCP-7875-1 4. A solution consisting primarily of Hydrogen Peroxide, Peracetic acid, and trace levels of various antimicrobial agents 5. Medical facility derived infections 6. Previously dubbed Hume Absorbent Chaperonin Complex 1 (HACC1) 7. In a manner visually akin to necrotizing fasciitis 8. Primarily responsible for DNA repair and recombination in numerous bacterial species, usually in response to various external stressors 9. The intended target of this experiment 10. V149 was the targeted variant of this experiment 11. An .AIC created by Dr. Xenia Galanis, primarily used to clarify microscopy imaging _cc_licenseboxbacteriabiohazardcontagionketerreality-bendingscp page revision: 5, last edited: 29 Dec 2023 06:05 Edit Rate (+30) Tags Discuss (4) History Files Print Site tools + Options Edit Sections Append Edit Meta Watchers Backlinks Page Source Parent Lock Page Rename Delete Help  | Terms of Service  | Privacy  | Report a bug  | Flag as objectionable Powered by Wikidot.com Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License Click here to edit contents of this page.
Click here to toggle editing of individual sections of the page (if possible). Watch headings for an "edit" link when available.
Append content without editing the whole page source.
Check out how this page has evolved in the past.
If you want to discuss contents of this page - this is the easiest way to do it.
View and manage file attachments for this page.
A few useful tools to manage this Site.
See pages that link to and include this page.
Change the name (also URL address, possibly the category) of the page.
View wiki source for this page without editing.
View/set parent page (used for creating breadcrumbs and structured layout).
Notify administrators if there is objectionable content in this page.
Something does not work as expected? Find out what you can do.
General Wikidot.com documentation and help section.
Wikidot.com Terms of Service - what you can, what you should not etc.
Wikidot.com Privacy Policy.
